Ajax Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ajax Therapeutics, Inc. - overview
Established
2019
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2019 by co-founders Ross Levine MD, Olli Silvennoinen, and Martin Vogelbaum (CEO), Ajax Therapeutics, Inc. operates as a provider of next-generation JAK2 inhibitors and targeted therapies for hematologic cancers to pharmaceutical companies and oncology research institutions. In April 2024, Ajax Therapeutics, Inc. raised USD 95 million in Series C funding led by Goldman Sachs Alternatives, with participation from Eli Lilly & Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital, Boxer Capital, Schrödinger, Inc.
, and Inning One Ventures. The company provides a wide range of therapeutic solutions, such as selective Type II JAK2 inhibitors for hematologic cancers, including myeloproliferative neoplasms (MPNs).
Current Investors
Schrodinger, LLC , Memorial Sloan-Kettering Cancer Center Pension Plan, EcoR1 Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ajaxtherapeutics.com/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.